Overview: Anti-MOG Antibody TestIntroduction: The Anti-MOG Antibody Test detects antibodies linked to neurological conditions like optic neuritis, causing vision loss or muscle weakness. Following 2023 AAN guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected demyelinating disorders.
Other Names: Anti-MOG Assay, Myelin Oligodendrocyte Glycoprotein Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Demyelinating disease antibody testing advanced in the 2000s. Anti-MOG assays emerged in the 2010s, and by the 2020s, immunoassays improved detection of neurological disorders.
Purpose: Diagnoses demyelinating disorders like optic neuritis, guides treatment, and monitors disease activity in patients with vision loss or muscle weakness.
Test Parameters: 1. Anti Myelin Oligodendrocyte Glycoprotein Antibody
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like vision loss or muscle weakness, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neurological symptoms, autoimmune disease history, or family history of demyelinating disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy or imaging.
Procedural Considerations: Uses an immunoassay to measure anti-MOG antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm demyelinating disorders, prompting immunosuppressive therapy. Negative results may require other antibody tests.
Specialist Consultation: Consult a neurologist for result interpretation. A neuro-ophthalmologist referral is advised for optic neuritis cases.
Additional Supporting Tests: Anti-NMDA antibody test, brain MRI, or CSF analysis to confirm demyelinating disorders or assess disease extent.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Results require clinical correlation.
References: AAN Demyelinating Disease Guidelines, 2023; Neurology, Reindl M, 2022.
